Tubulin inhibition represents an established target in the field of anticancer research, and over the last 20 years, an intensive search for new antimicrotubule agents has occurred. Indeed, in silico models have been presented that might aid the discovery of novel agents. Among these, a 7‐point pharmacophore model has been recently proposed. As a formal proof of this model, we carried out a ligand‐based virtual screening on the colchicine‐binding site. In vitro testing demonstrated that two compounds displayed a cytotoxic profile on neuroblastoma cancer cells (SH‐SY5H) and one had an antitubulinic profile. An intensive search for new antimicrotubule agents has occurred. Indeed, in silico models have been presented that might aid the discovery of novel agents. Among these, a 7‐point pharmacophore model has been recently proposed. As a formal proof of this model, we carried out a ligand‐based virtual screening on the colchicine binding site. In vitro testing demonstrated that two compounds displayed a cytotoxic profile on neuroblastoma cancer cells (SH‐SY5H) and one had an antitubulinic profile.